These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 19962528)

  • 21. Re: Patterns of recurrence and outcomes following induction bacillus Calmette-Guerin for high risk Ta, T1 bladder cancer s. P. Lerner, C. M. Tangen, H. Sucharew, D. Wood and E. D. Crawford J Urol 2007; 177: 1727-1731.
    Lamm DL
    J Urol; 2008 Feb; 179(2):788. PubMed ID: 18082825
    [No Abstract]   [Full Text] [Related]  

  • 22. The limits of bacillus Calmette-Guerin for carcinoma in situ of the bladder.
    Kim JC; Steinberg GD
    J Urol; 2001 Mar; 165(3):745-56. PubMed ID: 11176460
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Restaging transurethral resection of high risk superficial bladder cancer improves the initial response to bacillus Calmette-Guerin therapy.
    Herr HW
    J Urol; 2005 Dec; 174(6):2134-7. PubMed ID: 16280743
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [The influence over the long-term prognosis of BCG therapy and the surgical treatment in superficial bladder cancer treatment].
    Higashi S; Matsui Y; Takahashi T; Nishiyama H; Ito N; Yamamoto S; Kamoto T; Ogawa O
    Hinyokika Kiyo; 2005 Aug; 51(8):529-31. PubMed ID: 16164268
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Patterns of recurrence and outcomes following induction bacillus Calmette-Guerin for high risk Ta, T1 bladder cancer.
    Lerner SP; Tangen CM; Sucharew H; Wood D; Crawford ED
    J Urol; 2007 May; 177(5):1727-31. PubMed ID: 17437798
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Editorial comment.
    Kassouf W
    J Urol; 2010 Aug; 184(2):469. PubMed ID: 20620400
    [No Abstract]   [Full Text] [Related]  

  • 27. Re: can restaging transurethral resection of T1 bladder cancer select patients for immediate cystectomy? H. W. Herr, S. M. Donat and G. Dalbagni J Urol 2007; 177: 75-79.
    Nieder AM; Soloway MS; Jewett MA
    J Urol; 2007 Jul; 178(1):352. PubMed ID: 17507038
    [No Abstract]   [Full Text] [Related]  

  • 28. Editorial comment on: P0 stage at radical cystectomy for bladder cancer is associated with improved outcome independent of traditional clinical risk factors.
    Colombo R
    Eur Urol; 2007 Sep; 52(3):774-5. PubMed ID: 17434255
    [No Abstract]   [Full Text] [Related]  

  • 29. Editorial comment on: P0 stage at radical cystectomy for bladder cancer is associated with improved outcome independent of traditional clinical risk factors.
    Brausi M
    Eur Urol; 2007 Sep; 52(3):775-6. PubMed ID: 17434253
    [No Abstract]   [Full Text] [Related]  

  • 30. Tumor associated macrophages: predicting bacillus Calmette-Guerin immunotherapy outcomes.
    Brandau S
    J Urol; 2009 Apr; 181(4):1532-3. PubMed ID: 19230928
    [No Abstract]   [Full Text] [Related]  

  • 31. [The BCG as coadjuvant in the treatment of bladder carcinoma].
    Rodrigues Netto N; Caserta Lemos G; de Belis N
    Arch Esp Urol; 1979; 32(5):417-26. PubMed ID: 507944
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study.
    Lamm DL; Blumenstein BA; Crissman JD; Montie JE; Gottesman JE; Lowe BA; Sarosdy MF; Bohl RD; Grossman HB; Beck TM; Leimert JT; Crawford ED
    J Urol; 2000 Apr; 163(4):1124-9. PubMed ID: 10737480
    [TBL] [Abstract][Full Text] [Related]  

  • 33. What is the optimal BCG dose in non-muscle-invasive bladder cancer?
    Witjes JA
    Eur Urol; 2007 Nov; 52(5):1300-2. PubMed ID: 17531374
    [No Abstract]   [Full Text] [Related]  

  • 34. Bladder cancer--resection/ablation.
    Corica FA; Keane TE
    Surg Oncol Clin N Am; 2005 Apr; 14(2):321-52. PubMed ID: 15817242
    [No Abstract]   [Full Text] [Related]  

  • 35. Update on the Dutch Cooperative Trial: mitomycin versus bacillus Calmette-Guérin-Tice versus bacillus Calmette-Guérin RIVM in the treatment of patients with pTA-pT1 papillary carcinoma and carcinoma in situ of the urinary bladder. Dutch South East Cooperative Urological Group.
    Witjes WP; Witjes JA; Oosterhof GO; Debruyne MJ
    Semin Urol Oncol; 1996 Feb; 14(1 Suppl 1):10-6. PubMed ID: 8727805
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [T1 G3 bladder tumors: the respective role of BCG and cystectomy].
    Pfister C; Landé P; Hervé JM; Barré P; Barbagelatta M; Camey M; Botto H
    Prog Urol; 1995 Apr; 5(2):231-7. PubMed ID: 7719369
    [TBL] [Abstract][Full Text] [Related]  

  • 37. T1G3 transitional cell carcinoma of the bladder: recurrence, progression and survival.
    McHugh LA; Griffiths TR
    BJU Int; 2004 Jul; 94(1):193. PubMed ID: 15217467
    [No Abstract]   [Full Text] [Related]  

  • 38. Unmet Clinical Needs and Future Perspectives in Non-muscle-invasive Bladder Cancer.
    Campi R; Seisen T; Roupret M
    Eur Urol Focus; 2018 Jul; 4(4):472-480. PubMed ID: 30172757
    [No Abstract]   [Full Text] [Related]  

  • 39. Initial high-grade T1 urothelial cell carcinoma: feasibility and prognostic significance of lamina propria invasion microstaging (T1a/b/c) in BCG-treated and BCG-non-treated patients.
    Orsola A; Trias I; Raventós CX; Español I; Cecchini L; Búcar S; Salinas D; Orsola I
    Eur Urol; 2005 Aug; 48(2):231-8; discussion 238. PubMed ID: 15963635
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bacillus Calmette-Guérin therapy in stage Ta/T1 bladder cancer: prognostic factors for time to recurrence and progression.
    Andius P; Holmäng S
    BJU Int; 2004 May; 93(7):980-4. PubMed ID: 15142147
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.